Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC
Clinical trial NCT05056337 · UNKNOWN
Trial details
- NCT number
- NCT05056337
- Sponsor
- Shanghai Zhongshan Hospital
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-01
- Primary completion
- 2023-11-01
- Enrollment
- 220
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.